Mepolizumab 300 mg

DRUG5 trials

Sponsors

GlaxoSmithKline, University of North Carolina, Chapel Hill, Azienda Ospedaliero Universitaria di Cagliari, European EGPA Study Group, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

Chronic Rhinosinusitis (CRS) With and Without Nasal PolypsEGPA - Eosinophilic Granulomatosis With PolyangiitisEoEEosinophilic AsthmaEosinophilic EsophagitisEosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)Hypereosinophilic SyndromeSevere Asthma

Phase 2

Mepo for Eosinophilic Esophagitis (EoE) Study

CompletedNCT03656380

University of North Carolina, Chapel HillEoE, Eosinophilic Esophagitis

Start: 2019-03-20End: 2022-12-09Updated: 2023-08-23

Phase 3

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

CompletedNCT02836496

GlaxoSmithKlineHypereosinophilic Syndrome

Start: 2017-03-07End: 2019-08-08Updated: 2020-02-21

Phase 4

Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

Enrolling by invitationNCT07343661

Azienda Ospedaliero Universitaria di CagliariEGPA - Eosinophilic Granulomatosis With Polyangiitis, Eosinophilic Asthma, Severe Asthma

Start: 2025-10-17End: 2028-09-30Target: 90Updated: 2026-01-15

Unknown Phase

Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)

CompletedNCT07591753

European EGPA Study GroupEosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)

Start: 2025-09-18End: 2026-03-31Updated: 2026-09-11

Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300

CompletedNCT07592104

Fondazione Policlinico Universitario Agostino Gemelli IRCCSChronic Rhinosinusitis (CRS) With and Without Nasal Polyps, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Sinus Disease

Start: 2025-09-12End: 2026-03-23Updated: 2026-05-18

Related Papers

Research Communication: Mepolizumab Improves Histologic Severity as Measured by the <scp>EoEHSS</scp> in Adolescents and Adults With Eosinophilic Oesophagitis in a Multicenter, Randomised, Double‐Blind, Placebo‐Controlled Clinical Trial

Alimentary Pharmacology & Therapeutics2025-05-29

Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial

Gut2023-07-0978 citations

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine2023-03-299 citations

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome

Frontiers in Immunology2022-08-266 citations

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.

2022-05-1218 citations

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Frontiers in Immunology2022-04-137 citations